News | Stents Peripheral | April 28, 2017

New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent

Biotronik's bare metal stent proves effective and versatile as standalone and in combination with drug-coated balloon

New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent

April 28, 2017 — Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the 12-month results of the BIOFLEX PEACE all-comers registry. The findings were presented this week at the Charing Cross Symposium, April 25-28 in London. Outcomes of the BIOLUX 4EVER study were also presented on the main stage, revealing 12-month results numerically comparable to drug-eluting stents (DES) when the Pulsar-18 was used in combination with the Passeo-18 Lux drug-coated balloon (DCB).

The 12-month results from the BIOFLEX PEACE All-Comers Registry revealed findings for the first time for the entire patient cohort for the Pulsar-18 in the treatment of femoral popliteal lesions in a real-world setting. During the presentation at the Charing Cross Symposium, lead investigator Michael Lichtenberg, M.D., highlighted the 73.6 percent primary patency and 96.2 percent freedom from clinically driven target lesion revascularization (fTLR) in 164 patients. “These results are in line with already published data for the Pulsar stent from controlled trials, thus confirming the stent’s efficacy for a broader range of patients and lesions,” commented Lichtenberg, Vascular Center Clinic, Arnsberg, Germany.

In the BIOLUX 4EVER trial, physicians used the combination of the Pulsar-18 BMS and the Passeo-18 Lux DCB to treat superficial femoral artery (SFA) lesions. Koen Deloose, M.D., AZ Sint-Blasius, Dendermonde, Belgium presented the full 12-month (395 days) outcomes of this trial, with 89.9 percent primary patency and 91.6 percent fTLR in a cohort of 120 patients.

“The 12-month outcomes of the BIOLUX 4EVER trial indicate the value of a combined approach that provides physicians with more options and versatility when treating SFA lesions while achieving DES-like results,” commented Deloose. “While DES is limited by the need to fully cover the lesion with a stent and fully treat the lesion with paclitaxel, the new combination approach of a DCB and BMS means that there is now the freedom to determine how much support is necessary based on each vessel’s unique anatomy and lesion characteristics for a more tailored approach. Following full lesion coverage with the DCB, if full lesion stenting is deemed necessary, we have the results of BIOLUX 4EVER to give physicians the confidence of a good outcome; should the physician decide to minimize the metal burden, partial (focal) stenting can be used, which is not an option with DES.”

For more information: www.biotronik.com

Related Content

Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Cook Medical Recalls Transseptal Needle Due to Risk of Detached Plastic Fragments
News | Cath Lab | March 20, 2019
March 20, 2019 — Cook Medical is recalling one lot of its...
Overlay Init